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ABSTRACT: Tetrahydroisoquinoline (THIQ) alkaloids are
an important group of compounds that exhibit a range of
bioactivities. Here, a phosphate buﬀer-catalyzed Pictet−
Spengler reaction (PSR) using unreactive ketone substrates
is described. A variety of 1,1′-disubstituted and spiro-
tetrahydroisoquinoline alkaloids were readily prepared in
one-step and high yields, highlighting the general applicability of this approach. This study features the role of phosphate in the
aqueous-based PSR and provides an atom-eﬃcient, sustainable route to new THIQs.
■ INTRODUCTION
Tetrahydroisoquinolines (THIQs) are an important group of
pharmacologically active compounds exhibiting for example,
anticancer, antimalarial, analgesic, antithrombotic, and central
nervous system-related activities. A subgroup of THIQs, the
benzylisoquinoline alkaloids (BIAs) are a key family of natural
products found in higher plants and mammals.1 The BIAs in
particular have attracted the attention of many researchers in
recent years, giving rise to a range of patents and
publications.2−8 Amongst the THIQs, 1,1′-spiro compounds
have proven to be synthetically challenging to synthesize, and
they include the antiplasmodial compound 1, natural product
ochotensines 2 and 3, and trabectedin 4 (Figure 1).9−11
Diﬀerent strategies have been used to access THIQs,
including natural product extraction from plant sources,
aﬀording the desired alkaloids in low yields. In recent years,
eﬀorts have also been focused on the expression of biocatalysts
for use in the stereoselective synthesis of these alkaloids. For
example, in plants norcoclaurine synthases (NCSs) catalyze the
ﬁrst committed step in the BIA biosynthetic pathway, between
dopamine 5 and 4-hydroxyphenyl acetaldehyde (4-HPAA) and
they have been used in the synthesis.12−15
The Pictet−Spenglerase NCS has proven to be particularly
tolerant towards a range of aldehydes and more recently has
been reported to accept ketones.16−20 While the use of NCS to
generate 1,1′-substituted THIQs is a particularly powerful
strategy in stereoselective synthesis, a complementary method
to access achiral compounds, or an approach that does not
necessitate the production of biocatalysts would also be highly
valuable.
Many methods have been reported for synthesizing THIQs
including the Pictet−Spengler or Bischler−Napieralski reac-
tions,21,22 but typically for these reactions, particularly when
using ketones, high temperatures, strong acids, or superacids
are required.23,24 An example includes the reaction of 1-(3-
hydroxyphenyl)-2-aminoethanol with cyclohexanone to give
a spirooxazolidine which when fused at 150 °C produces 1,1′-
spiro-hexanotetrahydroisoquinoline.25,26 Such reaction condi-
tions are however incompatible with less stable phenethyl-
amines such as catechols. To overcome some of these
problems, Lewis acid catalysts such as o-benzenedisulfona-
mide,27 titanium(IV) isopropoxide,28 or calcium bis-
1,1,1,3,3,3-hexaﬂuoroisopropoxide29 have been used (Scheme
1a,b), but there are inherent limitations associated with the
preparation of such catalysts including high costs or the
requirement of a drybox.29 In addition, the key phenolic
groups must be protected or side products can be formed.
Phosphate salts are a useful alternative due to the lower costs
and milder reaction conditions that can be used.30 Indeed, we
have previously reported the use of aqueous phosphate in a
Pictet−Spengler reaction (PSR) for the synthesis of THIQs
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Figure 1. Selected 1,1′-spiro tetrahydroisoquinoline alkaloids.
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(Scheme 1c).30 The reaction was extended to a range of
aromatic, aliphatic, and heterocyclic aldehydes, but not with
ketone substrates which are more sterically challenging and less
reactive.
Here, we describe the discovery that aqueous phosphate
reaction conditions can also be used to synthesize THIQs using
ketones. The reaction conditions were optimized and applied
to variously decorated phenethylamines and a wide range of
cyclic and acyclic ketones in high yield (Scheme 1d). Some of
the THIQs synthesized have also been reported to possess
interesting bioactivities, including antiparasitic properties.10
■ RESULTS AND DISCUSSION
Aqueous phosphate media have previously been used to
produce norcoclaurine from dopamine 5 and 4-HPAA via a
PSR, and the reaction was extended to a range of aldehyde
substrates.30 Despite this facile approach of using catechols to
generate THIQs, an extension to ketone substrates has
received little attention, other than the work by Tono et al.
who noted that acetone might couple with dopamine in
phosphate buﬀer (0.1 M, pH 7.2), although the product was
not characterized.31 In addition, the extraction of dopamine
from the Chinese yam with acetone was believed to form a
THIQ and the characterization of plant acetone extracts from
Aristolochia arcuata highlighted that a THIQ was formed from
dopamine and acetone.32,33 The main challenge with the PSR
reaction using ketones is the relatively low reactivity, which
when combined with the sensitivity of catechols can lead to the
formation of many side products. However, inspired by the
interesting NCS mediated PSR reaction with ketones it was
decided to investigate whether an aqueous biomimetic
phosphate-based approach could also be developed.19
First, to avoid side reactions because of the oxidation of
catechols, such as dopamine 5, the antioxidant sodium
ascorbate was added to the reactions.20 Cyclohexanone 6
was then used in a reaction with potassium phosphate (KPi, 1
M) with acetonitrile as the cosolvent at pH 6 and 70 °C and
surprisingly, the PSR product 7 was formed in 11% yield
(Table 1, entry 1). Because diﬀerent phosphate anions
predominate at diﬀerent pHs, at pH 6 the major ion is
H2PO4
−, alternative pHs were explored. Unsurprisingly, no
product 7 was observed at pH 4, due to dopamine protonation,
and pH 12 due to the oxidation of dopamine which is
prevalent at high basic pHs. However, at pH 9 the yield
increased to 16% (Table 1, entry 4; see Supporting
Information Figure S1 for further data on the eﬀect of pH).
A pH of 9 was then used as a suitable starting point for further
reaction optimization. Density functional theory (DFT) and
MP2 methods have been used in a theoretical study exploring
the phosphate-mediated PSR with 3-hydroxypehenethylamine
and formaldehyde, which suggested that the lowest energy
pathway required both HPO4
2− and H2PO4
− for optimal
catalysis in the phosphate biomimetic reaction.34 At pH 9,
HPO4
2− is the predominant anion present (with some
H2PO4
−) and can facilitate both the deprotonation of the
meta-phenolic OH and abstraction of 8a-H in the isoquinolone
intermediate.
Typically, a cosolvent was required when developing the
phosphate PSR reaction with aldehydes where aldehyde
solubility was poor so other cosolvents were investigated,
also with a view to enhancing yields. The polar aprotic solvents
dimethyl sulfoxide (DMSO), dimethylformamide (DMF), and
1,4-dioxane together with the polar protic solvents methanol,
ethanol, and isopropanol were investigated (Table 1 and
Supporting Information Figure S2). While DMSO had little
eﬀect on the yield, it decreased when using DMF, 1,4-dioxane,
and isopropanol. However, the reaction yields were higher with
ethanol (Table 1, entry 6) and in particular methanol which
was superior to other cosolvents (Table 1, entry 7), giving a
43% yield of 7. Further studies established that lower
proportions of methanol (10−40% v/v, data not shown)
generated similar yields of 7, and in the absence of a cosolvent,
36% of 7 was formed. This presumably reﬂects the fact that in
the case of 6 there were no solubility issues in water.
To improve the synthetic utility, the reaction temperature
was increased to 80 and 90 °C with little eﬀect. Upon
Scheme 1. (a,b) Reported Lewis Acid-Catalyzed PSRs with
Ketones; (c) Previous Aqueous Phosphate-Mediated PSRs
with Aldehydes; (d) PSRs with Ketones Reported in This
Work Table 1. Initial Optimization of the Model Reaction Using 5
and 6 To Give 7a
entry 6 (equiv) KPi pH co-solvent yield 7 (%)b
1 1.3 6 MeCN 11
2 1.3 4 MeCN 0
3 1.3 12 MeCN 0
4 1.3 9 MeCN 16
5 1.3 9 DMSO 14
6 1.3 9 EtOH 21
7 1.3 9 MeOH 43
8 1.3 9 none 36
9 2.0 9 MeOH 46
10 5.0 9 MeOH 81
11 10.0 9 MeOH 97
aReactions conditions: dopamine 5 (15−25 mM), cyclohexanone 6
(20−150 mM), and sodium ascorbate (1.0 equiv relative to
dopamine) on a 1 mL scale in 1 M KPi, pH 9 and 50% co-solvent
(v/v) at 70 °C. bYields were determined by analytical HPLC.
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increasing the number of equivalents of 6 from 1.3 to 2, 5, and
10 equiv, in the latter case, 7 was formed in quantitative yield
(Table 1, entry 11), so this was used in further experiments.
The eﬀect of using lower KPi concentrations was also
investigated using 5 and 6 (Supporting Information, Table
S1). Concentrations of 0.1−1 M KPi gave 7 in 97% yield, and
below 0.1 M the yield of 7 decreased. To ensure suﬃcient KPi
was present, a 0.3−0.5 M KPi concentration was therefore
selected. The eﬀect of the dopamine 5 concentration in the
reaction was also explored (Supporting Information, Table
S2). The yield remained constant with concentrations of up to
0.3 M, decreasing to 48% with 1 M of 5 when solubility issues
were encountered.
With optimized reaction conditions in hand, we were
curious to understand the requirements for phosphate in the
reaction. Alternative buﬀers or bases were used at pH 9
including KOH, KHCO3−K2CO3 (0.5 M), Na3BO3 (0.5 M),
and Na2SO3 (saturated) together with water alone (Supporting
Information, Table S3). When water, water adjusted to pH 9
using KOH, or Na3BO3 solution was used, 7 was formed in
trace amounts in reactions with 10 mM of 5 (Supporting
Information, Table S3). These increased to 8−15% yields in
reactions using 50 mM of 5 (Supporting Information, Table
S4). Interestingly, with KHCO3−K2CO3 and Na2SO3 at pH 9
yields of 24 and 43% with 10 mM 5 were noted, increasing to
63 and 89% with 50 mM 5, respectively. At both dopamine
concentrations the highest yields were still observed with KPi.
The role of phosphate in previous experiments for aldehyde
PSRs has been probed using DFT and MP2 methods in a
theoretical study.34 The proposed reaction scheme for 3-
hydroxyphenethylamine and formaldehyde involved both
HPO4
2− and H2PO4
− having a role in the formation of a
complex with the iminium intermediate, and after cyclization,
H2PO4
− assisting in the deprotonation at 8a-H of isoquino-
lone, while also being complexed to the amine proton. The
lower yields observed with KHCO3−K2CO3 of 24% (10 mM
5) and 63% (50 mM 5) may reﬂect that the trigonal planar
geometry of carbonate is unlikely to be able to perform a
similar role of deprotonation and amine proton complexation
as readily as H2PO4
− (or potentially HPO4
2−) in the re-
aromatization step, compared to tetrahedral phosphate. The
relatively high yields with Na2SO3 were interesting and may be
due to its trigonal pyramidal structure, enabling the rear-
omatization step in a similar fashion to KPi, combined with the
reducing environment it provides. Overall, KPi gave rise to the
highest yields and so was used in further experiments. It was
also noted that in the reaction between 5 and 6 for the KPi
concentrations used, no ortho-regioisomer was detected
presumably because of steric reasons.35
With suitable reaction conditions established, the general
applicability of the reaction was explored for the synthesis of a
range of 1,1′-disubstituted and spiro-THIQ alkaloids (Scheme
2). Reactions were monitored by 1H NMR spectroscopy
because of the reported challenges with product isolation.29 In
addition, to conﬁrm the NMR data, for several reactions, the
yields were conﬁrmed by high-performance liquid chromatog-
raphy (HPLC) analysis. The phosphate mediated PSR could
tolerate a range of methyl ketones, giving 8−12 in 54−95%
Scheme 2. Application of the Phosphate-Catalyzed PSR to Synthesize 1,1′-Disubstituted and Spiro-THIQ Alkaloidsa
aTypical reaction conditions: dopamine 5 (15−25 mM), ketone (20−150 mM), and sodium ascorbate (1.0 equiv relative to dopamine or the
corresponding phenethylamine) were reacted together on a 1 mL scale in 0.3 M KPi, pH 9 and methanol (50% v/v of methanol and ketone
combined) at 70 °C. Small scale reactions were performed in duplicate or triplicate. Yields were determined by 1H NMR spectroscopy with an
internal standard (maleic acid), and also by HPLC analysis (see Supporting Information, Table S5 for HPLC retention times) for several examples
to conﬁrm the data. b10 equiv of the corresponding ketones were used. c50 equiv of the corresponding ketones were used. All products were
isolated (yields are in brackets) either from these small scale reactions or larger reactions and puriﬁed, using the acid−base extraction method or
preparative HPLC, for characterization purposes.
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yield when using aliphatic ketones. The reaction yields were
greater for 8 and 9, reﬂecting the inﬂuence of the increasing
alkyl chain length and associated steric eﬀects in the
intermediates and subsequent cyclizations to give products
10−12. For the aromatic ketones acetophenone or phenyl
acetone giving 13 and 14, respectively, again poor reactivities
were observed, reﬂecting unfavorable steric interactions in the
cyclization step to generate the THIQs. The introduction of a
triﬂuoromethyl group, however, was readily achieved giving 15
in 93% yield.
The introduction of a third cyclic or heterocyclic ring could
more widely be introduced into the THIQ scaﬀold, following
the model reaction to give 7. Using 3- or 4-methyl
cyclohexanone readily gave 16 and 17 in 70 and 80% yields,
respectively. Similarly, with 4-isopropyl cyclohexanone, 18 was
generated in 75% yield and using tetrahydro-4H-pyran-4-one
19 was formed in 83% yield. When using cyclobutanone and
cyclopentanone THIAs 20 and 21 were formed in 97 and 95%
yields, comparable yields to when using 6, highlighting that
other ring sizes can be readily used in the phosphate-catalyzed
Pictet−Spengler condensation. Furthermore, the use of 1- or 2-
indanone aﬀorded the tetracyclic ochotensine9 derivatives 22
and 23 in 70 and 21% yields, respectively.
In addition to using alternative ketone substrates, selected
substituted phenethylamines were investigated (Scheme 2). 2-
(3-Hydroxyphenyl)ethylamine20 was used with 6 to synthesize
24, a compound previously synthesized in 2 steps in 10% yield,
and reported to possess antimalarial properties.10 A yield of
74% was achieved and the product was isolated by preparative
HPLC in 53% yield. The ﬂuorinated analogue 4-ﬂuoro-3-
hydroxy phenethylamine was also used to give 25 in 55% yield.
A regioisomer of dopamine, 5-(2-aminoethyl)benzene-1,3-
diol,36 which will provide more unfavorable steric interactions
was investigated and gave 26 in a reasonable 57% yield.
To highlight the utility of this methodology, the synthesis of
7 and 20 as selected compounds were then performed on a 1 g
scale. The reaction yields by 1H NMR spectroscopy were 97%,
and at this larger scale it was possible to isolate the materials
using an acid−base extraction method to give 7 in 40% yield
and 20 in 51% yield.
The use of a ketone possessing ester functionality for
subsequent ring cyclization was also investigated to establish a
reaction cascade to form an additional ring, as this strategy
with an aldehyde had been successfully used to generate the
antibacterial trolline.20 Using the ketone KPi reaction
conditions established, 5 was reacted with commercially
available methyl levulinate 27 to form a linear intermediate
28 with a C-1 quaternary carbon. Spontaneous cyclization
by nucleophilic attack of the amine at the ester carbonyl,
following the favored 5-exo-trig mode, aﬀorded lactam 29 in
50% yield (by 1H NMR spectroscopy) (Scheme 3).
■ CONCLUSIONS
In summary, a biomimetic approach for the synthesis of 1,1′-
disubstituted and spiro-THIQs has been established using a
PSR with unactivated ketones. The reaction is readily
performed in methanol/phosphate buﬀer at pH 9 and 70
°C; these are signiﬁcantly milder reaction conditions than
those previously reported. The reaction successfully used
methyl ketones, cyclic ketones, and aromatic ketones with
phenethylamines bearing a meta-hydroxyl group. Overall, this
study provides a low cost and sustainable way of making C-1,1′
disubstituted THIQ alkaloids using phosphate buﬀer, to aﬀord
a range of products in high yields using a facile procedure.
■ EXPERIMENTAL SECTION
General Information. All chemicals were obtained from
commercial suppliers and used as received. Small-scale reactions
were heated using a BIOER Mixing block MB-102, and the scale-up
reactions were heated using a Heidolph MR Hei-Tec type heating
mantle. Thin layer chromatography was carried out using Merck TLC
silica gel 60 F254 plates, and the products were visualized using
combinations of UV light (254 nm), potassium permanganate, and
phosphomolybdic acid staining solutions. Column chromatography
was carried out using silica gel (particle size 40−60 μm). Infrared
(IR) spectra were recorded using a PerkinElmer Spectrum 100 FT-IR
spectrometer or a Bruker ALPHA PLATINUM-ATR, operating in the
ATR mode. 1H NMR spectra were recorded on Bruker AVANCE
400, 500, 600, and 700 MHz spectrometers at 25 °C, using the
residual protic solvent stated as the internal standard. Chemical shifts
are quoted in ppm to the nearest 0.01 ppm using the following
abbreviations: s (singlet), d (doublet), t (triplet), q (quartet), qn
(quintet), sext (sextet), dd (doublet of doublets), dt (doublet of
triplets), and m (multiplet) deﬁned as all multipeak signals, where the
overlap or complex coupling of signals make deﬁnitive descriptions of
peaks diﬃcult. The coupling constants are deﬁned as J and measured
in Hz. 13C{1H} NMR spectra were recorded at 100, 125, 150, or 175
MHz on Bruker AVANCE 400, 500, 600, and 700 MHz
spectrometers at 25 °C using the stated solvent as the standard.
Chemical shifts are reported to the nearest 0.1 ppm. Melting points
were measured with a Gallenkamp apparatus, and were uncorrected.
Mass spectra were obtained using a Waters Acquity UPLC SQD
(using a linear gradient of 5−95% of acetonitrile over 5 min, with a
C8 column, and ﬂow rate of 0.6 mL/min) and the Waters LCT
Premier XE ESI Q-TOF mass spectrometer in the Department of
Chemistry, UCL.
Determination of Yields Using 1H NMR Spectroscopy. The
reactions were set up in duplicate (1 mL scale) in Eppendorf tubes
which were shaken at 70 °C for 20 h. The reaction mixture was
transferred to a round-bottomed ﬂask and evaporated to remove
methanol. Water was then removed using a freeze-drier to obtain a
solid, which was dissolved in a solution of maleic acid (CD3OD/D2O
= 1:3, 1 mL) and characterized by 1H NMR spectroscopy. The
concentration of the maleic acid was half of the starting material
dopamine. The peak integration of maleic acid proton (δ = 5.89 ppm)
was calibrated as 1.00, and the integration (×100%) of one of the
product aromatic protons was used to determine the NMR yield.
HPLC Methods. Analytical HPLC Methods. HPLC analysis was
carried out on an Agilent 1260 Inﬁnity HPLC with a mobile phase (A:
water with 0.1% TFA; B: acetonitrile) in a gradient of A/B = 90%/
10% at 0−1 min, A/B = 90%/10% to A/B = 30%/70% at 1−6 min,
100% B at 6−6.5 min, and A/B = 90%/10% at 6.5−10 min. Each
injection volume was 10 μL. The column was an ACE 5 C18 reverse
phase column (150 mm × 4.6 mm). The ﬂow rate was 1 mL/min and
Scheme 3. Application of the KPi-Catalyzed PSR with 27 in
a Cascade Reaction
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detection wavelength was 280 nm. The retention time of each
compound is given in the Supporting Information, Table S5.
Preparative HPLC Methods. Preparative HPLC was carried out on
a Dionex 580 HPLC system, including a P580 Pump, ASI-100
Automated Sample Injector, and PDA-100 Photodiode Array
Detector. A C18 reverse phase column, Agilent ZORBAX 300SB-
C18 (250 mm × 9.4 mm, 5 μm) was used for puriﬁcations. The
detection wavelength was 280 nm and the ﬂow rate was 2 mL/min.
Chromeleon Client Program software was used to monitor the HPLC
traces.
Method I: mobile phase (A: water with 0.1% TFA; B: acetonitrile
with 0.1% TFA) in a gradient of A/B = 95%/5% at 0−6 min, A/B =
95%/5% to A/B = 55%/45% at 6−10 min, A/B = 55%/45% at 10−15
min, A/B = 55%/45% to A/B = 10%/90% at 15−16 min, A/B =
10%/90% at 16−18 min, A/B = 10%/90% to A/B = 95%/5% at 18−
20 min, A/B = 95%/5% at 20−25 min.
Method II: mobile phase (A: water with 0.1% TFA; B: acetonitrile
with 0.1% TFA) in a gradient of A/B = 95%/5% at 0−10 min, A/B =
95%/5% to A/B = 5%/95% at 10−12 min, A/B = 5%/95% at 12−13
min, A/B = 5%/95% to A/B = 95%/5% at 13−14 min, A/B = 95%/
5% at 14−30 min.
Method III: mobile phase (A: water with 0.1% TFA; B: acetonitrile
with 0.1% TFA) in a gradient of A/B = 85%/15% at 0−30 min.
3′,4′-Dihydro-2H-spiro[cyclohexane-1,1′-isoquinoline]-
6′,7′-diol Hydrochloride19 (7·HCl). To a solution of dopamine
hydrochloride (19 mg, 0.10 mmol) and sodium ascorbate (20 mg,
0.10 mmol) in KPi buﬀer (0.3 M, pH 9, 0.5 mL) and methanol (0.5
mL), cyclohexanone (104 μL, 1.0 mmol) was added. The reaction
mixture was shaken at 70 °C for 18 h and monitored by analytical
HPLC. The reaction mixture was diluted to ∼7 mL with water and
directly puriﬁed using the preparative HPLC method I. Fractions were
combined, exchanged with HCl (1 M), and evaporated to obtain 7·
HCl (19 mg, 70%) as a solid. The NMR yield of the reaction (97%)
was determined following the general procedure described. The
reaction was scaled-up using 5·HCl (1.00 g, 5.27 mmol) sodium
ascorbate (1 equiv with respect to dopamine) in KPi buﬀer (0.3 M,
pH 9, 52.7 mL) and methanol (52.7 mL), and 6 was added (5.48 mL,
52.7 mmol). The reaction mixture was shaken at 70 °C for 20 h, and
then the pH was adjusted to 3 by the addition of HCl (2 M). The
solvent was removed in vacuo, and the residue suspended in
acetonitrile at 0 °C. Finally, the mixture was ﬁltered and the solvent
removed in vacuo to give 7·HCl (0.491 g, 40%). 1H NMR (600 MHz;
CD3OD): δ 6.76 (s, 1H), 6.57 (s, 1H), 3.41 (t, J = 6.4 Hz, 2H), 2.96
(t, J = 6.4 Hz, 2H), 2.10−1.97 (m, 4H), 1.88−1.77 (m, 3H), 1.70−
1.60 (m, 2H), 1.52−1.42 (m, 1H); 13C{1H} NMR (151 MHz;
CD3OD): δ 146.4, 146.0, 129.9, 123.1, 116.1, 113.3, 61.0, 38.6, 36.8,
26.2, 25.3, 21.7; m/z [ES+] 234 ([MH]+, 100%).
1,1-Dimethyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol Hy-
drochloride33 (8·HCl). Dopamine hydrochloride (9.5 mg, 0.050
mmol) and sodium ascorbate (10 mg, 0.050 mmol) were mixed in
KPi buﬀer (0.3 M, pH 9, 963 μL) in a capped Eppendorf tube.
Acetone (37 μL, 0.50 mmol) was then added and the reaction mixture
was shaken under argon at 70 °C. After 18 h, the acetone was
removed in vacuo. The remaining solution was freeze-dried and the
NMR yield (95%) was determined following the general procedure
described. The reaction was also performed in duplicate to conﬁrm
the NMR yield and these two reaction products were combined and
puriﬁed using the preparative HPLC method I. Fractions were
combined, exchanged with HCl (1 M) and evaporated at 55 °C to
obtain 8·HCl as a white solid (7.4 mg, 32%). 1H NMR (400 MHz;
CD3OD): δ 6.70 (s, 1H), 6.57 (s, 1H), 3.46 (t, J = 6.4 Hz, 2H, 3-H2),
2.96 (t, J = 6.4 Hz, 2H, 4-H2), 1.67 (s, 6H, 2 × CH3);
13C{1H} NMR
(100 MHz; CD3OD): δ 146.5, 146.2, 129.6, 122.3, 116.1, 112.7, 58.1,
38.8, 28.5, 26.0; m/z [ES+] 194 ([MH]+, 100%).
1-Ethyl-1-methyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol
Hydrochloride (9·HCl). To a solution of dopamine hydrochloride
(19 mg, 0.10 mmol) and sodium ascorbate (20 mg, 0.10 mmol) in
KPi buﬀer (0.3 M, pH 9, 1 mL) and methanol (0.55 mL), butanone
(0.45 mL, 5.0 mmol) was added. The reaction mixture was shaken at
70 °C for 18 h and monitored by analytical HPLC. The reaction
mixture was diluted to 25 mL with water, washed with ethyl acetate (3
× 20 mL), and evaporated in vacuo to remove residual ethyl acetate,
and then directly puriﬁed using preparative HPLC method II.
Fractions were combined, exchanged with HCl (1 M), and evaporated
to give 9·HCl (8.0 mg, 33%) as a white solid. The NMR yield of the
reaction (92%) was determined following the general procedure
described. mp 129−133 °C (H2O); νmax (ﬁlm) 2970, 2792, 1591,
1523 cm−1; 1H NMR (600 MHz; CD3OD): δ 6.64 (s, 1H), 6.58 (s,
1H), 3.50−3.36 (m, 2H), 3.03−2.84 (m, 2H), 2.02 (q, J = 7.2 Hz,
2H), 1.63 (s, 3H), 0.98 (t, J = 7.2 Hz, 3H); 13C{1H} NMR (151
MHz; CD3OD): δ 146.5, 146.1, 128.7, 122.9, 116.2, 113.0, 61.2, 39.0,
34.5, 26.0, 25.9, 8.1; m/z [ES+] 208 ([MH]+, 100%); m/z [HRMS
ES+] calcd for C12H18NO2, 208.1332 [MH]
+; found, 208.1332.
1-Methyl-1-propyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol
Hydrochloride (10·HCl). Dopamine hydrochloride (9.5 mg, 0.050
mmol) and sodium ascorbate (10 mg, 0.050 mmol) were mixed in
KPi buﬀer (0.3 M, pH 9, 500 μL) and methanol (235 μL) in a capped
Eppendorf tube. 2-Pentanone (265 μL, 2.50 mmol) was then added
and the reaction mixture was shaken under argon at 70 °C. After 20 h
the methanol was removed in vacuo and the NMR yield (78%) was
determined following the general procedure described. Two further
duplicate reactions were performed, and the two reaction products
were combined and puriﬁed using the preparative HPLC method I.
Fractions were combined, exchanged with HCl (1 M), and evaporated
at 55 °C to give 10·HCl (11 mg, 43%) as a white solid. mp 237−239
°C (H2O); νmax (ﬁlm) 3341, 3127, 2958, 1593, 1530 cm
−1; 1H NMR
(600 MHz; CD3OD): δ 6.65 (s, 1H), 6.58 (s, 1H), 3.49−3.37 (m,
2H), 3.03−2.83 (m, 2H), 1.98−1.90 (m, 2H), 1.64 (s, 3H), 1.49−
1.41 (m, 1H), 1.33−1.25 (m, 1H), 0.98 (t, J = 7.2 Hz); 13C{1H}
NMR (151 MHz; CD3OD): δ 146.5, 146.1, 128.9, 122.8, 116.2,
113.0, 60.9, 44.1, 39.0, 26.4, 26.0, 17.8, 14.4; m/z [ES+] 222 ([MH]+,
100%); m/z [HRMS ES+] calcd for C13H20NO2, 222.1489 [MH]
+;
found, 222.1489.
1-Butyl-1-methyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol
Hydrochloride (11·HCl). Dopamine hydrochloride (9.5 mg, 0.050
mmol) and sodium ascorbate (10 mg, 0.050 mmol) were mixed in
KPi buﬀer (0.3 M, pH 9, 500 μL) and methanol (191.6 μL) in a
capped Eppendorf tube. 2-Hexanone (308.4 μL, 2.50 mmol) was then
added and the reaction mixture was shaken under argon at 70 °C.
After 20 h the NMR yield (54%) was determined following the
general procedure described. Two further duplicate reactions were
performed, and these two reaction products were combined and
puriﬁed using the preparative HPLC method III. Fractions were
combined, exchanged with HCl (1 M), and freeze dried to give 11·
HCl (4.6 mg, 34%) as a white solid. mp > 250 °C (H2O); νmax (ﬁlm)
3255, 2957, 1599, 1392 cm−1; 1H NMR (600 MHz; CD3OD): δ 6.65
(s, 1H), 6.58 (s, 1H), 3.49−3.38 (m, 2H), 3.04−2.93 (m, 1H), 2.89
(dt, J = 17.0, 5.4 Hz, 1H), 2.00−1.93 (m, 2H), 1.63 (s, 3H), 1.45−
1.32 (m, 3H), 1.29−1.19 (m, 1H), 0.94 (t, J = 7.2 Hz); 13C{1H}
NMR (151 MHz; CD3OD): δ 146.5, 146.1, 128.9, 122.8, 116.2,
113.0, 60.9, 41.7, 39.0, 26.5, 26.4, 25.9, 23.9, 14.2; m/z [ES+] 236
([MH]+, 100%); m/z [HRMS ES+] calcd for C14H22NO2, 236.1648
[MH]+; found, 236.1645.
1-(But-3-en-1-yl)-1-methyl-1,2,3,4-tetrahydroisoquinoline-
6,7-diol Hydrochloride (12·HCl). Dopamine hydrochloride (9.5
mg, 0.050 mmol) and sodium ascorbate (10 mg, 0.050 mmol) were
mixed in KPi buﬀer (0.3 M, pH 9, 500 μL) and methanol (210.4 μL)
in a capped Eppendorf tube. 5-Hexen-2-one (289.6 μL, 2.50 mmol)
was then added and the reaction mixture was shaken under argon at
70 °C. After 20 h the NMR yield (60%) was determined following the
general procedure described. Two further duplicate reactions were
performed, and the two reaction products were combined and
puriﬁed using the preparative HPLC method III. Fractions were
combined, exchanged with HCl (1 M), and freeze dried to give 12·
HCl (5.4 mg, 41%) as a white solid. mp > 250 °C (H2O); νmax (ﬁlm)
3196, 2957, 1672, 1616, 1369 cm−1; 1H NMR (600 MHz; CD3OD):
δ 6.67 (s, 1H), 6.59 (s, 1H), 5.82 (dt, J = 16.9, 10.3 Hz, 1H), 5.09
(dd, J = 16.9, 1.5 Hz, 1H), 5.01 (br d, J = 10.3 Hz, 1H), 3.48−3.42
(m, 2H), 2.99−2.96 (m, 1H), 2.95−2.89 (m, 1H), 2.24−2.15 (m,
1H), 2.08−2.01 (m, 3H), 1.67 (s, 3H); 13C{1H} NMR (151 MHz;
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CD3OD): δ 146.6, 146.2, 137.9, 128.5, 122.9, 116.24, 116.18, 113.0,
60.8, 41.1, 39.1, 28.8, 26.4, 25.9; m/z [ES+] 234 ([MH]+, 100%); m/
z [HRMS ES+] calcd for C14H20NO2, 234.1489 [MH]
+; found,
234.1490.
1-Methyl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol
Hydrochloride (13·HCl). To a solution of dopamine hydrochloride
(95 mg, 0.50 mmol) and sodium ascorbate (100 mg, 0.50 mmol) in
KPi buﬀer (0.3 M, pH 9, 5 mL) and methanol (2.08 mL),
acetophenone (2.92 mL, 25 mmol) was added. The reaction mixture
was heated at 70 °C for 20 h and the methanol removed in vacuo.
The product was extracted with ethyl acetate (3 × 15 mL) and the
organic phases combined, dried, and evaporated. The residue was
suspended in dimethyl carbonate (10 mL) and HCl (10 mL, 1 M)
and the aqueous phase was washed with dimethyl carbonate (3 × 5
mL) and then evaporated to obtain the crude product. This was
dissolved in water−acetonitrile (1:1) and directly puriﬁed using the
preparative HPLC method III. Fractions were combined, exchanged
with HCl (1 M), and evaporated to give 13·HCl (6.0 mg, 4.1%) as a
pale yellow solid. The NMR yield of the reaction (11%) was
determined following the general procedure described. mp > 200 °C
decomposed (H2O); νmax (ﬁlm) 3208, 2961, 2783, 1585 cm
−1; 1H
NMR (600 MHz; CD3OD): δ 7.45−7.39 (m, 3H), 7.35−7.30 (m,
2H), 6.69 (s, 1H), 6.47 (s, 1H), 3.42−3.35 (m, 1H), 3.15−3.05 (m,
2H), 2.98−2.92 (m, 1H), 2.13 (s, 3H); 13C{1H} NMR (151 MHz;
CD3OD): δ 147.2, 146.2, 142.0, 130.4, 130.1, 129.1, 128.0, 123.9,
116.0, 114.6, 63.3, 39.1, 27.3, 25.8; m/z [ES+] 256 ([MH]+, 100%);
m/z [HRMS ES+] calcd for C16H18NO2, 256.1332 [MH]
+; found,
256.1332.
1-Benzyl-1-methyl-1,2,3,4-tetrahydroisoquinoline-6,7-diol
Hydrochloride19 (14·HCl). To a solution of dopamine hydro-
chloride (56 mg, 0.30 mmol) and sodium ascorbate (60 mg, 0.30
mmol) in KPi buﬀer (0.3 M, pH 9, 10 mL) and methanol (10 mL),
phenyl acetone (400 μL, 3.0 mmol) was added. The reaction mixture
was heated at 70 °C for 18 h and the methanol removed in vacuo.
The product was extracted with ethyl acetate (3 × 20 mL) and the
organic phases combined, dried, and evaporated. The residue was
resuspended in dimethyl carbonate (10 mL) and HCl (10 mL, 1 M)
and the aqueous phase was washed with dimethyl carbonate (4 × 5
mL) and then evaporated to obtain the crude product. This was
dissolved in water−acetonitrile (1:1) and was puriﬁed (twice) using
the preparative HPLC method III. Fractions were combined,
exchanged with HCl (1 M), and evaporated to give 14·HCl (2.4
mg, 3%). The NMR yield of the reaction (25%) was determined
following the general procedure described. 1H NMR (700 MHz;
CD3OD): δ 7.36−7.29 (m, 3H), 7.18−7.15 (m, 2H), 6.63 (s, 1H),
6.60 (s, 1H), 3.36−3.32 (m, 3H), 3.25 (d, J = 14.0 Hz, 1H), 2.93 (t, J
= 6.3 Hz, 2H), 1.67 (s, 3H); 13C{1H} NMR (176 MHz; CD3OD): δ
146.6, 145.8, 135.3, 131.8, 129.6, 128.7, 127.9, 122.9, 116.0, 113.5,
60.8, 47.1, 39.0, 26.5, 25.6; m/z [ES+] 270 ([MH]+, 100%).
1-Ethyl-1-(triﬂuoromethyl)-1,2,3,4-tetrahydroisoquinoline-
6,7-diol Hydrochloride (15·HCl). To a solution of dopamine
hydrochloride (19 mg, 0.10 mmol) and sodium ascorbate (20 mg,
0.10 mmol) in KPi buﬀer (0.3 M, pH 9, 1 mL) and methanol (0.32
mL), 1,1,1-triﬂuoro-2-butanone (0.68 mL, 5.0 mmol) was added. The
reaction mixture was heated at 70 °C for 18 h and monitored by
analytical HPLC. The reaction mixture was directly puriﬁed using the
preparative HPLC method I. Fractions were combined, exchanged
with HCl (1 M), and evaporated to give 15·HCl (26 mg, 88%) as a
white solid. The NMR yield of the reaction (93%) was determined
following the general procedure described. mp 115−117 °C (H2O);
νmax (ﬁlm) 3130, 3042, 1526 cm
−1; 1H NMR (600 MHz; CD3OD): δ
6.81 (s, 1H), 6.70 (s, 1H), 3.60−3.45 (m, 2H), 3.04 (dt, J = 17.4, 6.3
Hz, 1H), 2.96 (dt, J = 17.4, 6.0, 1H), 2.45−2.35 (m, 2H), 1.06 (t, J =
7.8 Hz, 3H); 13C{1H} NMR (151 MHz; CD3OD): δ 148.4, 146.6,
126.2 (1JCF = 285 Hz, CF3), 126.1, 117.4, 116.7, 113.9, 65.9 (
2JCF =
26.7 Hz, CCF3), 41.6, 28.7, 25.6, 7.8; m/z [ES+] 262 ([MH]
+,
100%); m/z [HRMS ES+] calcd for C12H15F3NO2, 262.1049 [MH]
+;
found, 262.1049.
3-Methyl-3′,4′-dihydro-2′H-spiro[cyclohexane-1,1′-isoqui-
noline]-6′,7′-diol Hydrochloride19 (16·HCl). Dopamine hydro-
chloride (9.5 mg, 0.050 mmol) and sodium ascorbate (10 mg, 0.050
mmol) were mixed in KPi buﬀer (0.3 M, pH 9, 500 μL) and methanol
(438.7 μL) in a capped Eppendorf tube. 3-Methylcyclohexanone
(61.3 μL, 0.50 mmol) was then added and the reaction mixture was
shaken under argon at 70 °C. After 20 h the NMR yield (70%) was
determined following the general procedure described. Two further
duplicate reactions were performed, and the two reaction products
were combined and puriﬁed using the preparative HPLC method I.
Fractions were combined, exchanged with HCl (1 M), and freeze
dried to give 16·HCl (8.7 mg, 61%) as a solid. mp > 250 °C (H2O);
νmax (ﬁlm) 3196, 2947, 1594, 1394 cm
−1; 1H NMR (600 MHz;
CD3OD): δ 6.73 (s, 1H), 6.57 (s, 1H), 3.42−3.39 (m, 2H), 2.96−
2.94 (m, 2H), 2.08−1.99 (m, 2H), 1.93 (td, J = 14.6, 4.4 Hz, 1H),
1.88−1.81 (m, 2H), 1.78−1.69 (m, 1H), 1.68−1.60 (m, 2H), 1.13
(dq, J = 12.6, 4.2 Hz, 1H), 1.00 (d, J = 6.3 Hz, 3H); 13C{1H} NMR
(151 MHz; CD3OD): δ 146.5, 146.1, 129.6, 123.0, 116.1, 113.2, 61.7,
45.3, 38.7, 36.3, 34.1, 28.3, 26.2, 22.5, 21.6; m/z [HRMS ES+] calcd
for C15H22NO2, 248.1651 [MH]
+; found, 248.1664.
4-Methyl-3′,4′-dihydro-2′H-spiro[cyclohexane-1,1′-isoqui-
noline]-6′,7′-diol Hydrochloride19 (17·HCl). Dopamine hydro-
chloride (9.5 mg, 0.050 mmol) and sodium ascorbate (10 mg, 0.050
mmol) were mixed in KPi buﬀer (0.3 M, pH 9, 500 μL) and methanol
(438.7 μL) in a capped Eppendorf tube. 4-Methylcyclohexanone
(61.3 μL, 0.50 mmol) was then added and the reaction mixture was
shaken under argon at 70 °C. After 20 h the NMR yield (80%) was
determined following the general procedure described. Two further
duplicate reactions were performed, and the two reaction products
were combined and puriﬁed using the preparative HPLC method I.
Fractions were combined, exchanged with HCl (1 M), and freeze
dried to give 17·HCl (9.5 mg, 67%) as a solid. mp > 250 °C (H2O);
νmax (ﬁlm) 3196, 2947, 1594, 1394 cm
−1; 1H NMR (600 MHz;
CD3OD): δ 6.73 (s, 1H), 6.57 (s, 1H), 3.41 (t, J = 6.4 Hz, 2H), 2.95
(t, J = 6.4 Hz, 2H), 2.10−2.05 (m, 4H), 1.78 (dd, J = 15.0, 1.8 Hz,
2H), 1.69−1.60 (m, 1H), 1.36−1.22 (m, 2H), 1.03 (d, J = 6.5 Hz,
3H); 13C{1H} NMR (151 MHz; CD3OD): δ 146.5, 146.1, 129.5,
123.2, 116.1, 113.2, 60.6, 38.7, 36.9, 32.4, 30.1, 26.2, 22.2; m/z
[HRMS ES+] calcd for C15H22NO2, 248.1651 [MH]
+; found,
248.1661.
4-Isopropyl-3′,4′-dihydro-2′H-spiro[cyclohexane-1,1′-iso-
quinoline]-6′,7′-diol Hydrochloride (18·HCl). Dopamine hydro-
chloride (9.5 mg, 0.050 mmol) and sodium ascorbate (10 mg, 0.050
mmol) were mixed in KPi buﬀer (0.3 M, pH 9, 500 μL) and methanol
(463 μL) in a capped Eppendorf tube. 4-Isopropylcyclohexanone (70
mg, 0.50 mmol) was then added and the reaction mixture was shaken
under argon at 70 °C. After 20 h the NMR yield (75%) was
determined following the general procedure described. Two further
duplicate reactions were performed, and the two reaction products
were combined and puriﬁed using the preparative HPLC method III.
Fractions were combined, exchanged with HCl (1 M), and freeze
dried to give 18·HCl (8.3 mg, 53%) as a white solid. mp > 250 °C
(H2O); νmax (ﬁlm) 3223, 2931, 1652, 1524 cm
−1; 1H NMR (600
MHz; CD3OD): δ 6.73 (s, 1H), 6.57 (s, 1H), 3.41 (t, J = 6.4 Hz, 2H),
2.95 (t, J = 6.4 Hz, 2H), 2.08 (m, 4H), 1.91−1.84 (m, 2H), 1.57−
1.48 (m, 1H), 1.34−1.25 (m, 3H), 0.97 (d, J = 6.8 Hz, 6H); 13C
NMR (151 MHz; CD3OD): δ 146.5, 146.1, 129.5, 123.2, 116.1,
113.2, 60.9, 44.1, 38.8, 37.2, 33.9, 26.3, 25.5, 20.3; m/z [ES+] 276
([MH]+, 100%); m/z [HRMS ES+] calcd for C17H26NO2, 276.1958
[MH]+; found, 276.1960.
2′,3,3′,4,5′,6′-Hexahydro-2H-spiro[isoquinoline-1,4′-
pyran]-6,7-diol Hydrochloride (19·HCl). Dopamine hydrochloride
(9.5 mg, 0.050 mmol) and sodium ascorbate (10 mg, 0.050 mmol)
were mixed in KPi buﬀer (0.3 M, pH 9, 500 μL) and methanol (453.8
μL) in a capped Eppendorf tube. Tetrahydro-4H-pyran-4-one (46.2
μL, 0.50 mmol) was then added and the reaction mixture was shaken
under argon at 70 °C. After 20 h the NMR yield (83%) was
determined following the general procedure described. Two further
duplicate reactions were performed, and the two reaction products
were combined and puriﬁed using the preparative HPLC method III.
Fractions were combined, exchanged with HCl (1 M), and freeze
dried to give 19·HCl (8.9 mg, 65%) as a white solid. mp 200 °C
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decomposed (H2O); νmax (ﬁlm) 3223, 2969, 1591, 1525 cm
−1; 1H
NMR (600 MHz; CD3OD): δ 6.79 (s, 1H), 6.59 (s, 1H), 3.97 (dd, J
= 12.6, 4.5 Hz, 2H), 3.76 (td, J = 12.6, 2.0 Hz, 2H), 3.48 (t, J = 6.4
Hz, 2H), 2.98 (t, J = 6.4 Hz, 2H), 2.35 (ddd, J = 15.4, 12.6, 4.5 Hz,
2H), 2.00 (m, 2H); 13C{1H} NMR (151 MHz; CD3OD): δ 146.9,
146.3, 128.5, 123.4, 116.2, 113.4, 63.3, 58.7, 39.0, 36.8, 26.1; m/z [ES
+] 236 ([MH]+, 100%); m/z [HRMS ES+] calcd for C13H18NO3,
236.1281 [MH]+; found, 236.1282.
3′,4′-Dihydro-2′H-spiro[cyclobutane-1,1′-isoquinoline]-
6′,7′-diol Hydrochloride (20·HCl). Dopamine hydrochloride (9.5
mg, 0.050 mmol) and sodium ascorbate (10 mg, 0.050 mmol) were
mixed in KPi buﬀer (0.3 M, pH 9, 500 μL) and methanol (463 μL) in
a capped Eppendorf tube. Cyclobutanone (37 μL, 0.50 mmol) was
then added and the reaction mixture was shaken under argon at 70
°C. After 20 h the NMR yield (97%) was determined following the
general procedure described. Two further duplicate reactions were
performed, and the two reaction products were combined and
puriﬁed using the preparative HPLC method III. Fractions were
combined, exchanged with HCl (1 M), and freeze dried to give 20·
HCl (8.9 mg, 74%) as a white solid. The reaction was scaled-up using
5·HCl (1.00 g, 5.27 mmol) sodium ascorbate (1 equiv with respect to
dopamine) in KPi buﬀer (0.3 M, pH 9, 52.7 mL) and methanol (52.7
mL), and cyclobutanone was added (3.92 mL, 52.7 mmol). The
reaction mixture was shaken at 70 °C for 20 h, and then the pH was
adjusted to 3 by the addition of HCl (2 M). The solvent was removed
in vacuo, and the residue suspended in acetonitrile at 0 °C. Finally,
the mixture was ﬁltered and the solvent removed in vacuo to give 20·
HCl (0.646 g, 51%). mp > 250 °C (H2O); νmax (ﬁlm) 3155, 2947,
1578, 1398 cm−1; 1H NMR (600 MHz; CD3OD): δ 7.03 (s, 1H),
6.57 (s, 1H), 3.36 (t, J = 6.4 Hz, 2H), 2.93 (t, J = 6.4 Hz, 2H), 2.59 (t,
J = 8.3 Hz, 4H), 2.22 (m, 2H); 13C{1H} NMR (151 MHz; CD3OD):
δ 146.9, 146.4, 128.5, 122.8, 115.8, 112.4, 61.3, 39.5, 35.1, 26.1, 14.2;
m/z [ES+] 206 ([MH]+, 100%); m/z [HRMS ES+] calcd for
C12H16NO2, 206.1176 [MH]
+; found, 206.1176.
3′,4′-Dihydro-2′H-spiro[cyclopentane-1,1′-isoquinoline]-
6′,7′-diol Hydrochloride (21·HCl). Dopamine hydrochloride (9.5
mg, 0.050 mmol) and sodium ascorbate (10 mg, 0.050 mmol) were
mixed in KPi buﬀer (0.3 M, pH 9, 500 μL) and methanol (456 μL) in
a capped Eppendorf tube. Cyclopentanone (44 μL, 0.50 mmol) was
then added and the reaction mixture shaken under argon at 70 °C.
After 20 h the NMR yield (95%) was determined following the
general procedure described. Two further duplicate reactions were
performed, and the two reaction products were combined and
puriﬁed using the preparative HPLC method III. Fractions were
combined, exchanged with HCl (1 M), and freeze dried to give 21·
HCl (9.8 mg, 77%) as a solid. mp > 200 °C decomposed (H2O); νmax
(ﬁlm) 3223, 2970, 1592 cm−1; 1H NMR (600 MHz; CD3OD): δ 6.66
(s, 1H), 6.55 (s, 1H), 3.42 (t, J = 6.4 Hz, 2H), 2.95 (t, J = 6.4 Hz,
2H), 2.24−2.12 (m, 4H), 2.0−1.98 (m, 2H), 1.98−1.90 (m, 2H);
13C{1H} NMR (151 MHz; CD3OD): δ 146.5, 146.3, 129.6, 123.1,
115.8, 112.8, 68.8, 42.0, 40.3, 26.0, 25.9; m/z [ES+] 220 ([MH]+,
100%); m/z [HRMS ES+] calcd for C13H18NO2, 220.1332 [MH]
+;
found, 220.1329.
1,3,3′,4′-Tetrahydro-2′H-spiro[indene-2,1′-isoquinoline]-
6′,7′-diol Hydrochloride (22·HCl). Dopamine hydrochloride (56
mg, 0.30 mmol), sodium ascorbate (60 mg, 0.30 mmol), and 2-
indanone (396 mg, 3.0 mmol) were mixed in KPi buﬀer (0.3 M, pH 9,
10 mL) and methanol (10 mL). The reaction mixture was stirred at
70 °C for 18 h, and then diluted to 50 mL with water. The brown
insoluble precipitate was removed by ﬁltration and the ﬁltrate
extracted with ethyl acetate (4 × 20 mL). The organic phase was
washed with brine (2 × 20 mL), dried, ﬁltered, and evaporated to
obtain the crude product. The residue was washed with cold ethanol,
stirred in HCl (1 M) for 4 h and the solvent removed in vacuo (<55
°C) to give 22·HCl (38 mg, 57%) as a white solid. The NMR yield
(70%) was determined following the general procedure described. mp
> 240 °C decomposed (H2O); νmax (ﬁlm) 3396 (br), 1621, 1590,
1524 cm−1; 1H NMR (600 MHz; CD3OD): δ 7.35−7.27 (m, 4H),
6.60 (s, 1H), 6.56 (s, 1H), 3.60 (d, J = 17.1 Hz, 2H), 3.56 (d, J = 17.1
Hz, 2H), 3.51 (t, J = 6.6 Hz, 2H), 3.03 (t, J = 6.6 Hz, 2H); 13C{1H}
NMR (151 MHz; CD3OD): δ 147.0, 146.3, 140.0, 129.1, 128.9,
125.9, 122.9, 116.0, 112.1, 67.8, 48.1, 40.5, 26.0; m/z [ES+] 268
([MH]+, 100%); m/z [HRMS ES+] calcd for C17H18NO2, 268.1332
[MH]+; found, 268.1332.
2,3,3′,4′-Tetrahydro-2′H-spiro[indene-1,1′-isoquinoline]-
6′,7′-diol Hydrochloride (23·HCl). Dopamine hydrochloride (9.5
mg, 0.050 mmol), sodium ascorbate (10 mg, 0.050 mmol) and, 1-
indanone (66 mg, 0.5 mmol) were mixed in KPi buﬀer (0.3 M, pH 9,
500 μL) and methanol (500 μL) in a capped Eppendorf tube. The
reaction mixture was shaken under argon at 70 °C. After 20 h the
NMR yield (21%) was determined following the general procedure
described. Two further duplicate reactions were performed, and the
two reaction products were combined and puriﬁed using the
preparative HPLC method I. Fractions were combined, exchanged
with HCl (1 M), and solvent removed in vacuo (<55 °C) to give 23·
HCl (2.1 mg, 7%) as a white solid. mp > 240 °C decomposed (H2O);
νmax (ﬁlm) 3142, 2946, 2791, 1605, 1408 cm
−1; 1H NMR (700 MHz;
CD3OD): δ 7.48−7.42 (m, 2H), 7.32 (t, J = 7.0 Hz, 1H), 7.14 (d, J =
7.0 Hz, 1H), 6.66 (s, 1H), 6.16 (s, 1H), 3.60−3.48 (m, 2H), 3.30−
3.24 (m, 1H), 3.23−3.14 (m, 2H), 3.02 (dt, J = 16.8, 4.2 Hz, 1H),
2.81−2.72 (m, 1H), 2.60 (dt, J = 16.8, 8.4 Hz, 1H); 13C NMR (176
MHz; CD3OD): δ 146.9, 146.0, 145.9, 143.5, 131.3, 128.6, 127.6,
126.40, 126.36, 123.8, 115.5, 114.2, 71.8, 41.0, 40.0, 30.1, 25.6; m/z
[ES+] 268 ([MH]+, 100%); m/z [HRMS ES+] calcd for C17H18NO2,
268.1332 [MH]+; found, 268.1331.
3′,4′-Dihydro-2′H-spiro[cyclohexane-1,1′-isoquinolin]-6′-ol
Hydrochloride10 (24·HCl). 2-(3-Hydroxyphenyl)ethylamine hydro-
chloride20 (8.7 mg, 0.050 mmol) and sodium ascorbate (10 mg, 0.050
mmol) were mixed in KPi buﬀer (0.3 M, pH 9, 500 μL) and methanol
(241 μL) in a capped Eppendorf tube. Cyclohexanone (259 μL, 2.5
mmol) was added and the mixture was shaken under argon at 70 °C.
After 20 h the NMR yield (74%) was determined following the
general procedure described. Two further duplicate reactions were
performed, and the two reaction products were combined and then
puriﬁed using the preparative HPLC method I. Fractions were
combined, exchanged with HCl (1 M), and the solvent removed in
vacuo (<55 °C) to give 24·HCl (7.1 mg, 55%) as a solid. mp > 250
°C (H2O); νmax (ﬁlm) 3217, 2930, 2766, 1589, 1440 cm−1; 1H NMR
(700 MHz; CD3OD): δ 7.24 (d, J = 7.8 Hz, 1H), 6.74 (dd, J = 7.8, 2.1
Hz, 1H), 6.60 (d, J = 2.1 Hz, 1H), 3.45 (t, J = 6.3 Hz, 2H), 3.06 (t, J =
6.3 Hz, 2H), 2.09−2.03 (m, 4H), 1.87−1.79 (m, 3H), 1.70−1.62 (m,
2H), 1.55−1.45 (m, 1H); 13C{1H} NMR (176 MHz; CD3OD): δ
157.8, 133.1, 129.5, 128.1, 115.9, 115.7, 61.0, 38.2, 36.6, 26.7, 25.0,
21.5; m/z [ES+] 218 ([MH]+, 100%); m/z [HRMS ES+] calcd for
C14H20NO, 218.1539 [MH]
+; found, 218.1539.
7′-Fluoro-3′,4′-dihydro-2′H-spiro[cyclohexane-1,1′-isoqui-
nolin]-6′-ol Hydrochloride (25·HCl). To a solution of 2-(4-ﬂuoro-
3-hydroxyphenyl)ethylamine hydrobromide20 (23.6 mg, 0.10 mmol)
and sodium ascorbate (20 mg, 0.10 mmol) in KPi buﬀer (0.3 M, pH
9, 1 mL) and methanol (0.32 mL), cyclohexanone (518 μL, 5.0
mmol) was added. The reaction mixture was heated at 70 °C for 20 h
and the methanol was removed in vacuo. The solution was freeze-
dried, dissolved in water−acetonitrile (1:1), and centrifuged at 4000
rpm for 10 min. The supernatant was then puriﬁed by the preparative
HPLC method I. Fractions were combined, exchanged with HCl (1
M), and evaporated (at <55 °C) to give 25·HCl (14 mg, 50%) as a
white solid. The NMR yield of the reaction (55%) was determined
following the general procedure described. mp > 250 °C (H2O); νmax
(ﬁlm) 3150, 3061, 2942, 2762, 1525 cm−1; 1H NMR (600 MHz;
CD3OD): δ 7.18 (d,
3JHF = 12.6 Hz, 1H), 6.74 (d,
4JHF = 8.4 Hz, 1H),
3.45 (t, J = 6.2 Hz, 2H), 3.03 (t, J = 6.2 Hz, 2H), 2.11−1.97 (m, 4H),
1.89−1.74 (m, 3H), 1.73−1.59 (m, 2H), 1.56−1.42 (m, 1H);
13C{1H} NMR (151 MHz; CD3OD): δ 152.1 (d,
1JCF = 241 Hz),
145.9 (d, 2JCF = 13.4 Hz), 130.3, 128.4, 118.6 (d, JCF = 3.0 Hz), 114.4
(d, JCF = 21.0 Hz), 61.0, 38.4, 36.6, 26.3, 25.1, 21.6; m/z [ES+] 236
([MH]+, 100%); m/z [HRMS ES+] calcd for C14H19FNO, 236.1445
[MH]+; found, 236.1446.
5-(2-Aminoethyl)benzene-1,3-diol Hydrobromide.36 The
reaction was carried out under anhydrous conditions. To a solution
of 3,5-dimethoxyphenyl acetonitrile (753 mg, 4.25 mmol) in THF (10
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mL), borane−THF solution (1 M; 13 mL, 13 mmol) was added at 0
°C. The reaction was stirred for 24 h at room temperature, cooled to
0 °C, and methanol (30 mL) was added. The solution was then
stirred for another 24 h, concentrated under vacuum, and
coevaporated with methanol (3 × 10 mL). The residue was puriﬁed
by silica column chromatography (dichloromethane−methanol
(containing 1% triethylamine), 9:1 to 5:1) to give 2-(3,5-
dimethoxyphenyl)ethan-1-amine37 (427 mg, 55%) as an oil. Rf =
0.13 [dichloromethane−methanol (containing 1% triethylamine),
9:1]; 1H NMR (600 MHz; CDCl3): δ 6.36−6.34 (m, 2H), 6.32 (t,
J = 2.4 Hz, 1H), 3.77 (s, 6H), 2.96 (t, J = 7.2 Hz, 2H), 2.70 (t, J = 7.2
Hz, 2H), 2.12 (br s, 2H); 13C{1H} NMR (151 MHz; CDCl3): δ
161.0, 142.1, 107.0, 98.2, 55.4, 43.2, 40.0.
2-(3,5-Dimethoxyphenyl)ethan-1-amine (427 mg, 2.36 mmol) was
stirred in dichloromethane (20 mL) and boron tribromide (1 M; 7.5
mL, 7.5 mmol) at room temperature for 24 h. Methanol (30 mL) was
then added and the reaction stirred for another 3 h. The mixture was
then concentrated under vacuum and coevaporated with methanol to
give 5-(2-aminoethyl)benzene-1,3-diol·HBr36 (572 mg, 100%) as the
HBr salt. 1H NMR (600 MHz; CD3OD): δ 6.23 (d, J = 2.3 Hz, 2H),
6.19 (t, J = 2.3 Hz, 1H), 3.14 (t, J = 7.8 Hz, 2H), 2.82 (t, J = 7.8 Hz,
2H); 13C{1H} NMR (151 MHz; CD3OD): δ 160.0, 140.0, 108.2,
102.5, 41.9, 34.5; m/z [ES+] 154 ([MH]+, 100%).
3′,4′-Dihydro-2′H-spiro[cyclohexane-1,1′-isoquinoline]-
6′,8′-diol Hydrochloride (26·HCl). 3,5-Dihydroxyl phenethylamine
hydrobromide (11.7 mg, 0.050 mmol) and sodium ascorbate (10 mg,
0.050 mmol) were mixed in KPi buﬀer (0.3 M, pH 9, 500 μL) and
methanol (241 μL) in a capped Eppendorf tube. Cyclohexanone (259
μL, 2.5 mmol) was added and the mixture shaken under argon at 70
°C. After 20 h the NMR yield (57%) was determined following the
general procedure described. Two further duplicate reactions were
performed, and the two reaction products were combined and then
puriﬁed using the preparative HPLC method I. Fractions were
combined, exchanged with HCl (1 M), and the solvent removed in
vacuo (<55 °C) to give 26·HCl (5.0 mg, 37%) as a solid. mp > 250
°C (H2O); νmax (ﬁlm) 3232, 3092, 2861, 1590 cm
−1; 1H NMR (600
MHz; CD3OD): δ 6.23 (d, J = 2.4 Hz, 1H), 6.14 (d, J = 2.4 Hz, 1H),
3.34 (t, J = 6.0 Hz, 2H), 3.04−2.95 (m, 4H), 1.82−1.73 (m, 5H),
1.67−1.53 (m, 2H), 1.50−1.34 (m, 1H); 13C{1H} NMR (151 MHz;
CD3OD): δ 158.7, 157.1, 134.9, 116.1, 108.1, 103.8, 61.6, 38.3, 31.8,
28.0, 25.1, 21.6; m/z [ES+] 256 ([MNa]+, 29%), 234 ([MH]+, 75);
m/z [HRMS ES+] calcd for C14H20NO2, 234.1489 [MH]
+; found,
234.1489.
8,9-Dihydroxy-10b-methyl-1,5,6,10b-tetrahydropyrrolo-
[2,1-a]isoquinolin-3(2H)-one (29). Dopamine hydrochloride (9.5
mg, 0.050 mmol) and sodium ascorbate (10.5 mg, 0.053 mmol) were
mixed in KPi buﬀer (0.3 M, pH 9, 500 μL) and methanol (200 μL) in
a capped Eppendorf tube. Methyl levulinate 28 (300 μL, 2.5 mmol)
was added and the mixture shaken under argon at 70 °C for 20 h. A
duplicate reaction was performed, these two reactions were combined
and methanol removed in vacuo. The solution was freeze-dried and
the NMR yield of the reaction (50%) determined following the
general procedure described. The product was then puriﬁed using the
preparative HPLC method I. Fractions were combined, exchanged
with HCl (1 M), and the solvent removed in vacuo (<55 °C) to give
29·HCl (4.4 mg, 19%) as a white solid. mp > 237−238 °C (H2O);
νmax (ﬁlm) 3246 (br), 2966, 1644, 1520 cm
−1; 1H NMR (700 MHz;
CD3OD): δ 6.57 (s, 1H), 6.50 (s, 1H), 4.12 (dd, J = 13.3, 6.3 Hz,
1H), 3.11 (td, J = 13.3, 4.7 Hz, 1H), 2.75−2.69 (m, 1H), 2.67−2.60
(m, 2H), 2.41−2.33 (m, 2H), 2.06−2.00 (m, 1H), 1.49 (s, 3H);
13C{1H} NMR (176 MHz; CD3OD): δ 174.8, 145.4, 145.2, 134.9,
124.1, 116.0, 112.4, 62.8, 35.7, 35.4, 31.4, 28.6, 27.2; m/z [ES+] 234
([MH]+, 100%); m/z [HRMS ES+] calcd for C13H16NO3, 234.1125
[MH]+; found, 234.1126.
■ ASSOCIATED CONTENT
*S Supporting Information
The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/acs.joc.9b00527.
Supplementary ﬁgures and tables and 1H NMR and 13C
NMR spectra of all new products (PDF)
■ AUTHOR INFORMATION
Corresponding Author
*E-mail: h.c.hailes@ucl.ac.uk.
ORCID
Helen C. Hailes: 0000-0001-5574-4742
Notes
The authors declare no competing ﬁnancial interest.
■ ACKNOWLEDGMENTS
We gratefully acknowledge UCL Dean’s Prize and UCL-China
Scholarship Council Joint Research Scholarship for funding
J.Z. and the Biotechnology and Biosciences Research Council
(BBRSC) (BB/N01877X/1) for funding D.M.-S. We acknowl-
edge equipment support from the Engineering and Physical
Sciences Research Council (EPSRC) (EP/P020410/1). We
also thank K. Karu (UCL Mass Spectrometry Facility) and A.
E. Aliev (UCL NMR Facility) in the Department of Chemistry.
■ REFERENCES
(1) Dastmalchi, M.; Park, M. R.; Morris, J. S.; Facchini, P. Family
portraits: the enzymes behind benzylisoquinoline alkaloid diversity.
Phytochem. Rev. 2018, 17, 249−277.
(2) Stermitz, F. R.; Lorenz, P.; Tawara, J. N.; Zenewicz, L. A.; Lewis,
K. Synergy in a medicinal plant: Antimicrobial action of berberine
potentiated by 5-methoxyhydnocarpin, a multidrug pump inhibitor.
Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 1433−1437.
(3) Zou, Z.-h.; Lan, X.-b.; Qian, H.; Huang, W.-l.; Li, Y.-m. Synthesis
and evaluation of furoxan-based nitric oxide-releasing derivatives of
tetrahydroisoquinoline as anticancer and multidrug resistance reversal
agents. Bioorg. Med. Chem. Lett. 2011, 21, 5934−5938.
(4) Scott, J. D.; Williams, R. M. Chemistry and Biology of the
Tetrahydroisoquinoline Antitumor Antibiotics. Chem. Rev. 2002, 102,
1669−1730.
(5) Cortijo, J.; Villagrasa, V.; Pons, R.; Berto, L.; Martí-Cabrera, M.;
Martinez-Losa, M.; Domenech, T.; Beleta, J.; Morcillo, E. J.
Bronchodilator and anti-inflammatory activities of glaucine: In vitro
studies in human airway smooth muscle and polymorphonuclear
leukocytes. Br. J. Pharmacol. 1999, 127, 1641−1651.
(6) Kashiwada, Y.; Aoshima, A.; Ikeshiro, Y.; Chen, Y.-P.; Furukawa,
H.; Itoigawa, M.; Fujioka, T.; Mihashi, K.; Cosentino, L. M.; Morris-
Natschke, S. L.; Lee, K.-H. Anti-HIV benzylisoquinoline alkaloids and
flavonoids from the leaves of Nelumbo nucifera, and structure−
activity correlations with related alkaloids. Bioorg. Med. Chem. 2005,
13, 443−448.
(7) Scott, J. S.; Bailey, A.; Davies, R. D. M.; Degorce, S. L.; MacFaul,
P. A.; Gingell, H.; Moss, T.; Norman, R. A.; Pink, J. H.; Rabow, A. A.;
Roberts, B.; Smith, P. D. Tetrahydroisoquinoline Phenols: Selective
Estrogen Receptor Downregulator Antagonists with Oral Bioavail-
ability in Rat. ACS Med. Chem. Lett. 2016, 7, 94−99.
(8) Singh, I. P.; Shah, P. Tetrahydroisoquinolines in therapeutics: a
patent review (2010-2015). Expert Opin. Ther. Pat. 2017, 27, 17−36.
(9) Irie, H.; Kishimoto, T.; Uyeo, S. The total synthesis of
(±)-ochotensine and related compounds. J. Chem. Soc. C 1968,
3051−3057.
(10) Hanna, J. N.; Ntie-Kang, F.; Kaiser, M.; Brun, R.; Efange, S. M.
N. 1-Aryl-1,2,3,4-tetrahydroisoquinolines as potential antimalarials:
synthesis, in vitro antiplasmodial activity and in silico pharmacoki-
netics evaluation. RSC Adv. 2014, 4, 22856−22865.
(11) Toyoshima, R.; Mori, N.; Suzuki, T.; Lowtangkitcharoen, W.;
Suwanborirux, K.; Saito, N. Chemistry of Ecteinascidins. Part 5: An
Additional Proof of Cytotoxicity Evaluation of Ecteinascidin 770
Derivatives. Chem. Pharm. Bull. 2016, 64, 966−969.
The Journal of Organic Chemistry Article
DOI: 10.1021/acs.joc.9b00527
J. Org. Chem. XXXX, XXX, XXX−XXX
H
(12) Bonamore, A.; Rovardi, I.; Gasparrini, F.; Baiocco, P.; Barba,
M.; Molinaro, C.; Botta, B.; Boffi, A.; Macone, A. An enzymatic,
stereoselective synthesis of (S)-norcoclaurine. Green Chem. 2010, 12,
1623−1627.
(13) Ilari, A.; Franceschini, S.; Bonamore, A.; Arenghi, F.; Botta, B.;
Macone, A.; Pasquo, A.; Bellucci, L.; Boffi, A. Structural Basis of
Enzymatic (S)-Norcoclaurine Biosynthesis. J. Biol. Chem. 2009, 284,
897−904.
(14) Lichman, B. R.; Gershater, M. C.; Lamming, E. D.; Pesnot, T.;
Sula, A.; Keep, N. H.; Hailes, H. C.; Ward, J. M. Dopamine-first
mechanism enables the rational engineering of the norcoclaurine
synthase aldehyde activity profile. FEBS J. 2015, 282, 1137−1151.
(15) Lichman, B. R.; Sula, A.; Pesnot, T.; Hailes, H. C.; Ward, J. M.;
Keep, N. H. Structural Evidence for the Dopamine-First Mechanism
of Norcoclaurine Synthase. Biochemistry 2017, 56, 5274−5277.
(16) Pesnot, T.; Gershater, M. C.; Ward, J. M.; Hailes, H. C. The
Catalytic Potential of Coptis japonica NCS2 Revealed - Development
and Utilisation of a Fluorescamine-Based Assay. Adv. Synth. Catal.
2012, 354, 2997−3008.
(17) Ruff, B. M.; Bras̈e, S.; O’Connor, S. E. Biocatalytic production
of tetrahydroisoquinolines. Tetrahedron Lett. 2012, 53, 1071−1074.
(18) Nishihachijo, M.; Hirai, Y.; Kawano, S.; Nishiyama, A.; Minami,
H.; Katayama, T.; Yasohara, Y.; Sato, F.; Kumagai, H. Asymmetric
synthesis of tetrahydroisoquinolines by enzymatic Pictet-Spengler
reaction. Biosci., Biotechnol., Biochem. 2014, 78, 701−707.
(19) Lichman, B. R.; Zhao, J.; Hailes, H. C.; Ward, J. M. Enzyme
catalysed Pictet-Spengler formation of chiral 1,1′-disubstituted- and
spiro-tetrahydroisoquinolines. Nat. Commun. 2017, 8, 14883.
(20) Zhao, J.; Lichman, B. R.; Ward, J. M.; Hailes, H. C. One-pot
chemoenzymatic synthesis of trolline and tetrahydroisoquinoline
analogues. Chem. Commun. 2018, 54, 1323−1326.
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